BridgeBio Pharma Inc (BBIO)
30.10
-0.94
(-3.04%)
USD |
NASDAQ |
May 17, 16:00
30.10
0.00 (0.00%)
After-Hours: 20:00
BridgeBio Pharma Cash from Investing (Quarterly): 22.75M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 22.75M |
| December 31, 2023 | -0.066M |
| September 30, 2023 | 37.68M |
| June 30, 2023 | 4.119M |
| March 31, 2023 | 12.30M |
| December 31, 2022 | 17.96M |
| September 30, 2022 | 146.86M |
| June 30, 2022 | 149.70M |
| March 31, 2022 | 138.62M |
| December 31, 2021 | 21.80M |
| September 30, 2021 | 58.97M |
| June 30, 2021 | 0.458M |
| March 31, 2021 | -282.05M |
| Date | Value |
|---|---|
| December 31, 2020 | 83.02M |
| September 30, 2020 | -45.05M |
| June 30, 2020 | -128.98M |
| March 31, 2020 | 38.02M |
| December 31, 2019 | -16.90M |
| September 30, 2019 | -197.34M |
| June 30, 2019 | -0.583M |
| March 31, 2019 | -2.427M |
| December 31, 2018 | -3.599M |
| September 30, 2018 | -0.605M |
| June 30, 2018 | -1.655M |
| March 31, 2018 | -15.18M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-282.05M
Minimum
Mar 2021
149.70M
Maximum
Jun 2022
3.064M
Average
15.13M
Median
Cash from Investing (Quarterly) Benchmarks
| Pfizer Inc | 1.732B |
| Alnylam Pharmaceuticals Inc | -67.62M |
| Regenxbio Inc | 13.18M |
| ACADIA Pharmaceuticals Inc | -14.04M |
| Biomarin Pharmaceutical Inc | -14.24M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -219.54M |
| Cash from Financing (Quarterly) | 279.55M |
| Free Cash Flow | -605.72M |
| Free Cash Flow Per Share (Quarterly) | -1.237 |
| Free Cash Flow to Equity (Quarterly) | -210.23M |
| Free Cash Flow Yield | -11.89% |